knowledge -WSS

knowledge

author：Wikipedia 2025-09-27 12:56:53 - browse：2819

Adam's take main illustration — Molly Ferguson/STAT

Some day-after thoughts on Bristol Myers Squibb acquiring Mirati Therapeutics:

A take-under deal feels meh for biotech sector sentiment.Bristol is paying $58 per share in cash for Mirati, which closed Friday at $60. Granted, Mirati was trading in the $30 range in September, so from there, the roughly 50% premium isn’t terrible. But as Mizuho strategist Jared Holz pointed out, investors would liked to have seen Mirati go for $75-$100 per share.

With the closely watched XBI biotech index down 13% for the year, every M&A deal helps improve sentiment, but this one — maybe just a little. Bristol is paying $4.8 billion in cash to acquire Mirati, or $3.7 billion after accounting for Mirati’s cash. It’s a small bolt-on acquisition for Bristol, which isn’t overpaying.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Wildfire smoke exposes gaps in outdoor worker protections
Next article： When a patient nears the end, a feared therapy can comfort

WSS

Medicare drug price negotiation hearing pits pharma v Biden admin

IVF doctors demand details after CooperSurgical lawsuit

Readout Newsletter: The latest on Novo Nordisk, Alnylam, Apogee

Longer MASH drug regimen improved liver, Akero study finds

The stock market has soared this year, but will it last? Experts weigh in

Change Healthcare: What is it, why does its cyberattack matter?

Wikipedia

knowledge

leisure time

Novavax promises a turnaround & Lilly roils the obesity market

'Golden Bachelor' Gerry Turner reveals what he wants in a partner and more

Sports medicine is finally prioritizing gender equality

Change Healthcare: What is it, why does its cyberattack matter?

Psychedelics group wrestles with new pharma identity

After a decade, new Gardasil ad campaign gets it (mostly) right

Tori Bowie and the unacceptable rates of Black maternal death

He's 19 months old and has one of the world’s rarest diseases

23andMe had bad news about my health. I wish a person had delivered it

Microsoft's Peter Lee: Generative AI could help doctors be more human

hotspot

Lack of health data on LGBTQ+ people has serious consequences

5 dead in mass shooting on Caribbean island of St. Vincent: Police

Ancient Greek ideas underpin modern concepts of pregnancy

When a patient nears the end, a feared therapy can comfort

This biotech could one day make human eggs from scratch. But first, they’re trying to rethink IVF

First over

hotspot

hotspot

hotspot

entertainment